Piper Sandler Maintains Overweight Rating on Stryker Corporation (SYK)

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as one of the top 12 Medical Devices stocks to invest in according to Hedge Funds [1] - Matthew O'Brien from Piper Sandler has reiterated an Overweight rating on Stryker with a price target of $420, indicating over 17% upside potential for investors [1][2] - The company is introducing a new handheld orthopedic robot, Mako RPS, which is expected to enhance its market presence in lower-cost segments, including ambulatory surgical centers and select international markets [2] Group 2 - Evercore ISI has maintained an Outperform rating on Stryker while adjusting the target price from $405 to $390, citing recoveries in end markets and anticipated healthy capital expenditures in the medical technology sector for 2026 [3] - Stryker operates in two segments: MedSurg & Neurotechnology and Orthopaedic, focusing on innovative products to improve patient outcomes [4]